Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

GRWD 0715

Next Previous
Drug Profile

GRWD 0715

Alternative Names: GRWD-0715

Latest Information Update: 20 Aug 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Grey Wolf Therapeutics
  • Class Anti-inflammatories; Antirheumatics; Small molecules
  • Mechanism of Action ERAP1 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase I/II Axial spondyloarthritis
  • Preclinical Autoimmune disorders

Most Recent Events

  • 28 Jul 2025 Phase-I/II clinical trials in Axial spondyloarthritis (In volunteers) in Australia (PO) (NCT07047703)
  • 02 Jul 2025 Grey Wolf Therapeutics plans the phase I/II EAST-1 trial for Axial spondyloarthritis in Australia, Belgium, Germany, Netherlands (PO), in August 2025 (NCT07047703)
  • 31 Dec 2024 Preclinical trials in Axial spondyloarthritis in United Kingdom (PO) prior to December 2024 (Grey Wolf therapeutics pipeline, December 2024).

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top